MARLBOROUGH, Mass. & PRINCETON, N.J.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, for the treatment of generalized anxiety disorder (GAD). In addition to GAD, ulotaront is being investigated in late-stage clinical studies for the treatment of schizophrenia and for the adjunctive treatment of major depressive disorder (MDD).
Sumitomo Pharma is doing a little bit of spring cleaning to bring a handful of biopharma units under one consolidated company to be named Sumitomo Pharma America.
Sunovion Answers Is Named a J.D. Power 2022 Certified Customer Service Program?
Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder
Drug maker Lupin on Thursday said it will acquire two inhalation brands from Sunovion Pharmaceuticals Inc for USD 75 million (around Rs 622 crore). The drug firm has inked a pact with US-based Sunovion to acquire Brovana (arformoterol tartrate) inhalation solution and Xopenex HFA (levalbuterol tartrate) inhalation aerosol.
Lupin yesterday announced that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Arformoterol Tartrate inhalation solution 15 mcg (base)/2 ml, unit-dose Vialsto market, a generic equivalent of Brovana inhalation solution, 15 mcg/2 ml of Sunovion Pharmaceuticals Inc, Lupin notified in a statement.
MARLBOROUGH, Mass. & PRINCETON, N.J.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in SEP380-301, a Phase 3 clinical study evaluating non-racemic amisulpride (SEP-4199) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression). Non-racemic amisulpride is being jointly developed and commercialized as part of a collaboration between Sunovion, its parent company Sumitomo Dainippon Pharma and Otsuka Pharmaceutical Co., Ltd.
MARLBOROUGH, Mass. & OSAKA, Japan & TOKYO, Japan--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion),its parent company Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo Dainippon Pharma) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today that the companies have entered into a worldwide license agreement for the joint development and commercialization of four compounds: ulotaront (SEP-363856), non-racemic ratio of amisulpride enantiomers (SEP-4199), SEP-378614 and SEP-380135.
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has entered into an agreement with BIAL in which Sunovion has granted exclusive commercial license rights in Europe for apomorphine sublingual film (APL-130277). APL-130277, approved as KYNMOBI® (apomorphine hydrochloride) sublingual film in the U.S. and Canada, is a novel thin film formulation of apomorphine that dissolves under the tongue for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). APL-130277 is currently in Phase 3 clinical development in Europe.
With the debut of Urovant’s Gemtesa a few months underway, Sunovion is joining the sales and marketing effort for the overactive bladder treatment.